Core Insights - The global non-targeted metabolomics market is experiencing significant growth, with the market size expected to reach approximately $390 million by 2024, up from $190 million in 2021, reflecting a compound annual growth rate (CAGR) of 10.8% [8][6][13] - In China, the precision non-targeted metabolomics market is also expanding, with projected market sizes of $160 million in 2022, $200 million in 2023, and $240 million in 2024 [13][15] - The demand for precision non-targeted metabolomics is driven by advancements in biomedical research and the need for high-accuracy data in biomarker discovery and precision medicine [8][13] Market Overview - The global metabolomics market has grown from $1.72 billion in 2020 to an expected $2.59 billion by 2024, indicating a robust growth trajectory [6] - The precision non-targeted metabolomics segment is gaining traction, with its share of the overall metabolomics applications increasing from 10% in 2021 to an estimated 12% by 2024 [8] Competitive Landscape - Major players in the Chinese precision non-targeted metabolomics market include Baichu Bio, Zhongke New Life, and Nuohe Zhiyuan, indicating a concentrated market structure [15] - The new generation of metabolomics technology, particularly from Baichu Bio, shows significant advantages in substance identification levels and database size compared to traditional methods [2][3] Technological Advancements - The new generation metabolomics technology offers enhanced capabilities, including a larger standard substance database and improved detection stability across multiple centers [3] - The integration of high-throughput technologies and multi-omics approaches is expanding the applications of precision non-targeted metabolomics in various fields, including precision medicine and disease mechanism exploration [8][13]